<p>Biohaven Ltd. has announced the presentation of clinical safety and efficacy data for BHV-1510, a next-generation Trop2 antibody drug conjugate (ADC), in combination with the anti-PD-1 monoclonal antibody cemiplimab. The results were presented at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress held from December 10-12, 2025, in London, United Kingdom. In a Phase 1 trial involving pretreated patients with advanced or metastatic cancer, including those with prior PD-(L) 1 treatment, the combination of BHV-1510 and cemiplimab demonstrated confirmed objective response rates of 60% in non-small cell lung cancer (NSCLC), 100% in endometrial cancer, and 50% in urothelial cancer. The safety profile showed low rates of adverse events attributed to the unconjugated payload, with no cases of interstitial lung disease reported. The poster presentation is available on Biohaven’s website. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biohaven Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43154) on December 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

BHVN

<p>Biohaven Ltd. announced promising Phase 1 trial results for BHV-1510 combined with cemiplimab in advanced solid tumors. The trial showed high objective response rates: 60% in NSCLC, 100% in endometrial cancer, and 50% in urothelial cancer, with a favorable safety profile. Results were presented at the 2025 ESMO Immuno-Oncology Congress.</p>

Biohaven Reports Promising Phase 1 Results for BHV-1510 in Combination with Cemiplimab in Advanced Solid Tumors